CN114698844A - Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin - Google Patents
Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin Download PDFInfo
- Publication number
- CN114698844A CN114698844A CN202210373469.4A CN202210373469A CN114698844A CN 114698844 A CN114698844 A CN 114698844A CN 202210373469 A CN202210373469 A CN 202210373469A CN 114698844 A CN114698844 A CN 114698844A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- procyanidine
- procyanidin
- pentostatin
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 47
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229920002414 procyanidin Polymers 0.000 title claims abstract description 29
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 title claims abstract description 25
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 16
- 230000002496 gastric effect Effects 0.000 title claims abstract description 12
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 title claims description 16
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 title claims description 16
- 229960002340 pentostatin Drugs 0.000 title claims description 16
- 239000003814 drug Substances 0.000 claims abstract description 11
- 150000002972 pentoses Chemical class 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000003647 oxidation Effects 0.000 claims abstract description 8
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940015043 glyoxal Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- NLJWJVZWEDXGGN-UHFFFAOYSA-N 3-ethyl-1,2-benzothiazole-6-sulfonic acid Chemical compound C(C)C1=NSC2=C1C=CC(=C2)S(=O)(=O)O NLJWJVZWEDXGGN-UHFFFAOYSA-N 0.000 description 1
- -1 ABTS free radical Chemical class 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a chitosan procyanidin composition in inhibiting formation of gastrointestinal pentosan, belonging to the field of health-care food or medicines. The invention discovers that the effect of inhibiting the formation of the pentosan in the gastrointestinal tract can be obviously improved after the chitosan and the procyanidine are combined for use, and the oxidation resistance of the combination of the chitosan and the procyanidine is obviously stronger than that of the single chitosan or the procyanidine. The chitosan and the procyanidine or the composition containing the chitosan and the procyanidine can be used for preparing health-care food or medicine for inhibiting the formation of the pentose or resisting oxidation or treating, delaying or improving pentose related diseases, and has wide application prospects in the fields of oxidation resistance, aging resistance and diabetes resistance.
Description
Technical Field
The invention belongs to the field of health-care food or medicine, and relates to application of a chitosan procyanidin composition in inhibiting formation of pentose.
Background
Carbonyl compounds (e.g., reducing sugars) and amino compounds (e.g., amino acids, peptides, proteins, etc.) in food products undergo a series of oxidation, cyclization, dehydration, polymerization, etc. reactions at ambient or elevated temperatures to produce various maillard reaction products, such as pentosans. Pentosans are cross-linked forms of lysine and arginine residues, and high levels of pentosans adversely affect bone strength. The formation of the Maillard products can increase the oxidative stress and the active carbonyl stress level, induce the up-regulation of the expression level of inflammatory factors and further trigger diseases, such as insulin resistance, vascular injury and the like. The accumulation of pentosan in human body can be reduced by inhibiting the formation of pentosan, so as to reduce the risk of various chronic diseases.
Chitosan (chitosan) is a product of natural polysaccharide chitin with partial acetyl removed, has multiple physiological functions of biodegradability, biocompatibility, nontoxicity, bacteriostasis, cancer resistance, lipid reduction, immunity enhancement and the like, and is widely applied to various fields of food additives, textile, agriculture, environmental protection, beauty and health care, cosmetics, antibacterial agents, medical fibers, medical dressings, artificial tissue materials, drug slow release materials, gene transduction carriers, biomedical fields, medical absorbable materials, tissue engineering carrier materials, medical treatment, drug development and the like and other daily chemical industries.
Procyanidins (oligomeric proanthocyanidins, OPC) are bioflavonoids with a specific molecular structure and are currently internationally recognized natural antioxidants effective in scavenging free radicals in the human body. Generally a reddish brown powder, slightly smelling, astringent, soluble in water and most organic solvents. Experiments prove that the anti-free radical oxidation capacity of the OPC is 50 times of that of vitamin E and 20 times of that of vitamin C, the OPC is quickly and completely absorbed, the maximum blood concentration can be reached after the OPC is orally taken for 20 minutes, and the metabolism half-life period is 7 hours.
Disclosure of Invention
The invention aims to provide an application of a chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin.
The purpose of the invention is realized by the following technical scheme:
the invention discovers that chitosan and procyanidine can inhibit the formation of pentosan in the gastrointestinal tract, the effect of inhibiting the formation of pentosan in the gastrointestinal tract can be obviously improved after the chitosan and procyanidine are combined for use, and the combined antioxidant capacity of the chitosan and procyanidine is obviously stronger than that of the chitosan or procyanidine alone. Based on this discovery, chitosan and procyanidins or compositions containing chitosan and procyanidins have utility in inhibiting the formation of gastrointestinal pentosans. The chitosan and procyanidine or the composition containing chitosan and procyanidine have the application of preparing antioxidant health-care food or medicine.
Furthermore, the chitosan and the procyanidine or the composition containing the chitosan and the procyanidine have the application of preparing health-care food or medicine for inhibiting the formation of the pentose or treating, delaying or improving the pentose related diseases. The pentose element related diseases comprise diabetes, Alzheimer disease, atherosclerosis and other diseases.
A health food or medicine for inhibiting the formation of pentostatin or resisting oxidation or treating, delaying or improving the diseases associated with pentostatin contains chitosan and proanthocyanidin.
The chitosan procyanidin composition has stronger antioxidant capacity than that of the chitosan or procyanidin alone, and has more remarkable effect of inhibiting the generation of pentostatin in the gastrointestinal tract.
The chitosan procyanidin composition disclosed by the invention has a remarkable anti-pentose generation effect and a strong free radical scavenging capacity in the gastrointestinal tract, and has a wide application prospect in the fields of oxidation resistance, aging resistance and diabetes resistance.
Drawings
FIG. 1 is the pentostatin inhibition of different samples during the gastrointestinal digestion stage.
FIG. 2 shows the ABTS free radical clearance for different samples.
In FIGS. 1-2, the different letters a-c indicate that the difference is statistically significant (p < 0.05).
Detailed Description
The following examples are intended to further illustrate the invention but should not be construed as limiting it. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
Chitosan (MW 30000) used in the following examples was purchased from shanghai mclin biochemistry science and technology limited.
The procyanidins used in the examples below were prepared by the following method: extracting raw material lotus seed pot by established procyanidine extraction process (Chinese patent ZL 02115423.6) to obtain procyanidine crude extract, extracting the procyanidine crude extract with ethyl acetate for 3 times, collecting ethyl acetate phase, performing reduced pressure rotary evaporation and concentration at 40 ℃, and freeze drying to obtain refined procyanidine for the following experiments.
The solutions prepared in the following examples were all prepared with water as not described.
Example 1: pentostatin production inhibitor screening
(1) Procyanidin, chitosan, and chitosan procyanidin composition (chitosan procyanidin mass ratio 2: 1) were added to 4mL of artificial saliva (SSF, formulation method shown in Table 1) stock solution, respectively, to maintain the final concentration at 0.3 g/L. Then 25 mu L of 0.3mol/L CaCl is added2Then, 5mL of ultrapure water was added thereto. Adding 200mg Bovine Serum Albumin (BSA), 11.36. mu.L 8.8mol/L glyoxal (glyoxal, GO), and establishing a bovine serum albumin-glyoxal model. Mix well for 2 minutes as buccal group. The control group did not contain procyanidin, chitosan procyanidin composition.
Table 1 preparation of simulated digestive juice stock solution
| Composition (I) | SSF(mmol/L) | SGF(mmol/L) | SIF(mmol/L) |
| KCl | 15.1 | 6.9 | 6.8 |
| KH2PO4 | 3.7 | 0.9 | 0.8 |
| NaHCO3 | 13.6 | 25 | 85 |
| NaCl | — | 47.2 | 38.4 |
| MgCl2(H2O)6 | 0.15 | 0.1 | 0.33 |
| (NH4)2CO3 | 0.06 | 0.5 | — |
(2) In the step (1) 3.75mL stock solution of artificial gastric fluid (SGF, see Table 1) was added and the pH adjusted to 2.0 with 0.1mol/L HCl solution. Then 0.25mL of pepsin (80000U/mL), 2.5. mu. L0.3mol/L of CaCl were added2Finally, 10mL of ultrapure water was added thereto, and the mixture was digested in a 37 ℃ constant temperature shaking chamber for 2 hours to prepare a gastric digestion group.
(3) In step (2), 5.5mL of artificial intestinal fluid (SIF, formulation method shown in Table 1) stock solution was added, followed by 2.5mL of pancreatin (800U/mL), 1.25mL of fresh porcine bile salt (160mmol/L), and 20. mu.L of 0.3M CaCl2And adjusting the pH value to be neutral by NaOH (1mol/L) to inactivate enzyme. Supplementing to 20mL with ultrapure water, placing in a constant temperature oscillation box at 37 ℃ for digestion for 2h, boiling to inactivate enzyme after digestion, and using as an intestinal digestion group.
(4) The content of pentosan in different stages of the sample is determined by fluorescence intensity of Hitachi F-4700 fluorescence spectrophotometer at the excitation wavelength (lambda ex) 335nm and the emission wavelength (lambda em) 385nm by adopting a BSA-GO model.
Pentostatin inhibition (%) (1-A)Sample (A)/AControl)×100％
The results are shown in fig. 1, and fig. 1 is a graph of the rate of pentose inhibition of different samples during the gastrointestinal digestion stage, with the abscissa representing the digestion stage and the ordinate representing the rate of pentose inhibition. The inhibition rate of the sample on pentostatin is low in the oral phase, and the inhibition effect of the sample on pentostatin is obviously enhanced from the gastric phase. In the stomach stage and the intestine stage, chitosan and procyanidin have the inhibition capacity on pentostatin, but the inhibition rates of pentostatin of chitosan and procyanidin are weaker than that of the chitosan procyanidin composition, which indicates that the inhibition capacity of chitosan procyanidin on pentostatin has a synergistic effect in the gastrointestinal digestion stage.
Example 2: clearance rate of 2, 2' -azinobis (3-ethylbenzisothiazoline-6-sulfonic acid) dimonium salt (ABTS)
The method comprises the following steps:
(1) 7.4mmol/L ABTS was prepared.
(2) Preparation 2.6mmol/L K2S2O8。
(3) 0.2mL of each solution prepared in the steps (1) and (2) is mixed and reacted for 12h at room temperature in a dark environment.
(4) Diluted 30 times with methanol, and the value at 734nm measured by a microplate reader is 0.7 +/-0.02.
(5) Mixing 1mL of the solution obtained in step (4) with 0.1mL of methanol and 0.1mL of the above intestinal digestion group sample solution diluted by 10 times with water for 10s, shaking up, and standing for 6 min. As a control group and a sample group, respectively.
(6) The absorbance of each set of reaction solution at 734nm wavelength was measured with a microplate reader and zeroed with methanol.
ABTS clearance (%) - (a)Control-ASample (A))/AControl×100％。
The results are shown in fig. 2, where the chitosan ABTS clearance rate was 30.79%, the procyanidin ABTS clearance rate was 57.10%, and the chitosan procyanidin composition ABTS clearance rate was 89.39%. The composition has more significant ABTS scavenging ability than procyanidin and chitosan alone.
The foregoing description only represents the specific embodiments of the present application, and it should be noted that, for those skilled in the art, many changes and modifications can be made without departing from the technical spirit of the present application, and these changes and modifications all belong to the protection scope of the present application.
Claims (5)
1. Application of chitosan and procyanidin or composition containing chitosan and procyanidin in inhibiting formation of gastrointestinal pentostatin is provided.
2. Application of chitosan and procyanidin or composition containing chitosan and procyanidin in preparing antioxidant health food or medicine is provided.
3. Application of chitosan and procyanidine or composition containing chitosan and procyanidine in preparing health food or medicine for inhibiting formation of pentostatin is provided.
4. Application of chitosan and procyanidine or composition containing chitosan and procyanidine in preparing health food or medicine for treating, delaying or improving pentose related diseases.
5. A health food or medicine for inhibiting the formation of pentose or resisting oxidation or treating, delaying or improving pentose related diseases, which is characterized in that: comprises chitosan and procyanidin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210373469.4A CN114698844A (en) | 2022-04-11 | 2022-04-11 | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210373469.4A CN114698844A (en) | 2022-04-11 | 2022-04-11 | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114698844A true CN114698844A (en) | 2022-07-05 |
Family
ID=82173276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210373469.4A Pending CN114698844A (en) | 2022-04-11 | 2022-04-11 | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114698844A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115644433A (en) * | 2022-09-30 | 2023-01-31 | 湖北工业大学 | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005060338A (en) * | 2003-08-19 | 2005-03-10 | Toyo Shinyaku:Kk | Proanthocyanidin-including composition |
| US20110059162A1 (en) * | 2009-09-04 | 2011-03-10 | Jess Dreher Reed | Tannin-chitosan composites |
| CN103536583A (en) * | 2013-11-01 | 2014-01-29 | 张维芬 | Proanthocyanidin sustained release nano-micro spheres, as well as preparation method and application thereof |
| CN106852726A (en) * | 2017-01-17 | 2017-06-16 | 上海应用技术大学 | A kind of OPC microcapsules and preparation method thereof |
| CN107083067A (en) * | 2017-05-18 | 2017-08-22 | 北京化工大学 | A kind of isinglass containing OPC/chitosan edibility antibacterial oxidation-resistant film and preparation method thereof |
| CN108576191A (en) * | 2018-05-21 | 2018-09-28 | 遵义盛林农业发展有限公司 | A kind of preservation method for blueberry |
| CN110423789A (en) * | 2019-08-15 | 2019-11-08 | 青岛科技大学 | A kind of graft copolymer, the preparation method and application of chitosan and procyanidine |
| AU2020103918A4 (en) * | 2019-12-10 | 2021-02-11 | Sichuan Agricultural University | Method for preparing edible proanthocyanidin/gelatin/chitosan nanoparticle, product and application thereof |
-
2022
- 2022-04-11 CN CN202210373469.4A patent/CN114698844A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005060338A (en) * | 2003-08-19 | 2005-03-10 | Toyo Shinyaku:Kk | Proanthocyanidin-including composition |
| US20110059162A1 (en) * | 2009-09-04 | 2011-03-10 | Jess Dreher Reed | Tannin-chitosan composites |
| CN103536583A (en) * | 2013-11-01 | 2014-01-29 | 张维芬 | Proanthocyanidin sustained release nano-micro spheres, as well as preparation method and application thereof |
| CN106852726A (en) * | 2017-01-17 | 2017-06-16 | 上海应用技术大学 | A kind of OPC microcapsules and preparation method thereof |
| CN107083067A (en) * | 2017-05-18 | 2017-08-22 | 北京化工大学 | A kind of isinglass containing OPC/chitosan edibility antibacterial oxidation-resistant film and preparation method thereof |
| CN108576191A (en) * | 2018-05-21 | 2018-09-28 | 遵义盛林农业发展有限公司 | A kind of preservation method for blueberry |
| CN110423789A (en) * | 2019-08-15 | 2019-11-08 | 青岛科技大学 | A kind of graft copolymer, the preparation method and application of chitosan and procyanidine |
| AU2020103918A4 (en) * | 2019-12-10 | 2021-02-11 | Sichuan Agricultural University | Method for preparing edible proanthocyanidin/gelatin/chitosan nanoparticle, product and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| JING WANG ET AL.: "Inhibition of advanced glycation endproducts during fish sausage preparation by transglutaminase and chitosan oligosaccharides induced enzymatic glycosylation", 《FOOD &FUNCTION》, vol. 9, pages 253 * |
| QIAN WU: "Inhibition of advanced glycation endproducts formation by lotus seedpod oligomeric procyanidins through RAGE-MAPK signaling and NF-κB activation in high-AGEs-diet mice", 《FOOD AND CHEMICAL TOXICOLOGY》, vol. 156, no. 112481, pages 195 - 199 * |
| X IAOFANG PENG ET AL.: "Beneficial Effects of Cinnamon Proanthocyanidins on the Formation of Specific Advanced Glycation Endproducts and Methylglyoxal-Induced Impairment on Glucose Consumption", 《J. AGRIC. FOOD CHEM.》, vol. 58, pages 6692 * |
| 张莉等: "壳聚糖-原花青素高抗氧化抑菌薄膜的研究", 《包装工程》, vol. 41, no. 15, pages 103 - 109 * |
| 邓舜扬主编, 科学技术文献出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115644433A (en) * | 2022-09-30 | 2023-01-31 | 湖北工业大学 | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4470212B2 (en) | Skin improver | |
| KR100828494B1 (en) | A composition of a cosmetic essense and the method of prepating it for improvenent of wrinkle | |
| Pangestuti et al. | Green seaweeds-derived polysaccharides ulvan: Occurrence, medicinal value and potential applications | |
| CN113412875A (en) | Protein ultrasonic composite acid/alkali treatment combined with catechin to improve oxidation resistance | |
| CN114698844A (en) | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin | |
| Tokareva et al. | Heterocycles of natural origin as non-toxic reagents for cross-linking of proteins and polysaccharides | |
| JP6807535B2 (en) | Fibroblast growth factor | |
| WO2007131424A1 (en) | Method for preparing low molecular weight proteoglycan and collagen compositions, its products and uses | |
| CA2634345A1 (en) | Phaseolus vulgaris extracts, their use, and formulations containing them | |
| JP2010120869A (en) | Anti-aging agent, anti-inflammatory agent, bleaching agent and antioxidant agent | |
| KR100796904B1 (en) | Compositions for promoting hair growth containing complexes of stabilized Vitamin C or Vitamin C derivatives | |
| WO2008032134A1 (en) | Method for obtaining yeast glucan by autolysis of saccharomyces cerevisiae baker's yeast cells | |
| CN115894666A (en) | Preparation method of tuna skin collagen peptide zinc ion chelate | |
| CN114766665A (en) | Application of pachyman procyanidin composition in inhibiting formation of AGEs (advanced glycation end products) in gastrointestinal tract | |
| CN111820406B (en) | Polypeptide resveratrol preparation, preparation method and application thereof, and health-care product or pharmaceutical composition containing polypeptide resveratrol preparation | |
| JP3689413B2 (en) | Flavan compound-containing composition | |
| CN114711428A (en) | Application of pectin ECG composition in inhibiting formation of pyridine derivatives in gastrointestinal tract | |
| CN114712384B (en) | Application of chitosan EGCG composition in inhibiting formation of gastrointestinal cross-linking agent | |
| CN114698845B (en) | Application of pachyman EGC composition in inhibiting formation of gastrointestinal argininyl | |
| EP3756477A1 (en) | Nano collagen peptide chelate mineral and method for preparing the same | |
| KR20210115240A (en) | A method and composition of increasing absorption of minerals using PDRN and N-Acetylglucosamin as active ingredients | |
| KR20060130739A (en) | Water-soluble bound matter of proanthocyanidin and composition containing the same | |
| KR20210001042A (en) | Cosmetic composition for moisturizing skin and improving skin wrinkles containing nano collagen peptide chelate mineral | |
| CN107712587A (en) | A kind of anti-oxidant anti-aging nutrient powder and preparation method thereof | |
| KR100876921B1 (en) | Method for tenderizing shell of crustacean or animal horny substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220705 |
|
| RJ01 | Rejection of invention patent application after publication |